Gene Therapy R&D and Revenue Forecasts 2016-2026 : Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs

遺伝子治療の世界市場:研究開発および売上予測2016-2026

◆タイトル:Gene Therapy R&D and Revenue Forecasts 2016-2026 : Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs
◆商品コード:VGAIN6022516
◆調査・発行会社:visiongain
◆発行日:2016年1月
◆ページ数:145
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、遺伝子治療の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・遺伝子治療の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・遺伝子治療の世界市場:疾患別市場分析
・遺伝子治療の研究開発パイプライン分析・予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Gene Therapies – Discover Revenue Predictions and See How Treating Cancer, Cardiovascular Disorders and Other Chronic Diseases Progresses
What does the future hold for gene therapy? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.

Visiongain’s new 2016 report gives you revenue forecasts to 2026 for the world gene therapies market, submarkets and leading products. Avoid missing out. There investigate that applied molecular genetics, discovering its most promising uses.

See what gains are possible. Please read on to explore that industry and discover how high its revenues can go.

Scope of our analysis – the technologies whose potential you discover
In this report visiongain defines gene therapy as products modifying the expression of particular genes or correcting abnormal genes.

Therefore this study excludes some agents that may be considered as gene therapies under wider definitions, such as gene silencing and oligonucleotide therapies, antisense therapy and immune system stimulators.

Forecasts and other analyses showing opportunities in those genetic technologies
Besides revenue forecasting to 2026, our analyses show results, growth rates and market shares. There you find original analysis. Our work also explains research and development. In that new report you gain 46 tables, 25 charts and three interviews.

Now make your searching for data on gene therapies easier. Also save time and benefit your insight and authority. That way you can benefit your research, analysis and decisions, helping you see where progress and money lie.

Stay ahead in knowledge. See what is possible for the therapeutic delivery of nucleic acid polymers into patients’ cells to treat diseases. The following sections show how visiongain’s new investigation helps your work.

Prospects for the overall world market and segments – what is possible?
What are the secrets of that industry’s progress? Along with our prediction of the overall world market value for gene therapies, our study shows you individual revenue forecasting of five submarkets to 2026 at world level, with discussions:
• Cancer (oncology)
• Cardiovascular diseases
• Rare medical conditions, including inherited disorders
• Ophthalmological disorders
• Other applications of that genetic biotechnology in human healthcare.

Which segment will achieve highest sales? Which has fastest predicted revenue growth? See how and why those commercial uses in human healthcare will develop, prosper and gain in importance.

For developers, producers and sellers, assess how those next-generation medicines generate revenues. Also gauge potential successes from 2016, assessing the most lucrative applications.

Products – discover sales forecasting for leading gene therapies
Our study shows you individual revenue predictions to 2026 for two marketed products:
• Glybera
• Neovasculgen.

That report also discusses these brands: Gendicine and Oncorine. Our analyses include revenue forecasting to 2026 for these six drug candidates:
• GSK2696273 (GSK)
• Collategene/AMG0001 (AnGes MG/Vical)
• BC-819 (BioCancell)
• Lenti-D (Bluebird Bio)
• SPK-RPE65 (Spark Therapeutics)
• Invossa/TissueGene-C (TissueGene/Kolon Life Science).

In particular our investigation discusses 12 leading compounds in development. The market will expand through the approval and launch of many products from 2016.

That way see what is possible. The momentum of gene therapy R&D continues, with reportedly more than 2,000 clinical studies worldwide. Stay ahead in knowledge.

Our study explains what the future holds, discussing issues to help your work.

Developments, challenges and opportunities affecting researchers, producers and users
Our investigation lets you assess trends, R&D and outlooks for gene therapy. There you find discussions of forces, progress and potentials:
• Overcoming challenges when replacing dysfunctional genes, inactivating (knocking out) mutated DNA and introducing a modified gene
• Commercial prospects of gene addition, reprogramming and correction, as well as cell elimination
• Pricing, reimbursement and gaining acceptance of the treatments, expanding their use
• R&D – assess leading drug candidates, especially for treating cancer, cardiovascular diseases, genetic disorders and other hard-to-treat conditions
• Changing market shares – applications in oncology becoming more prominent, giving pharmaceutical companies many opportunities.

Our study discusses other influences, including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.

There you explore commercial strengths, weaknesses, opportunities and threats, assessing advances and prospects. You investigate what helps and restrains developers, producers and marketers of gene therapies, benefiting your authority.

Discover in our report what the past, present and future hold for those cellular technologies.

Gene therapies – what revenue could that overall world market earn in 2020?
From 2016 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for gene therapies will reach $204m in 2020, with potential to multiply further in sales to 2026.

Our report’s author said: “That emerging market attracts interest from pharma companies and technology providers, a trend likely to continue. Gene therapies in development will bring in a new era for disease treatment and make a difference in long-term benefits for patients.”

Visiongain’s new survey examines leading companies in that field. Organisations our investigation discusses include these:
• Bristol-Myers Squibb
• Pfizer
• Bayer Healthcare
• Novartis
• GSK
• uniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics.

【レポートの目次】

1. Report Overview
1.1 Global Gene Therapy Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to Gene Therapy
2.1 What is Gene Therapy?
2.2 Types of Gene Therapy
2.3 Products Excluded from the Report
2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2014-2026
3.1 The World Market for Gene Therapy: Overview of Products
3.2 Gendicine (rAd-p53) – The First Gene Therapy to Market
3.3 Oncorine: Growth is Hindered by Certain Factors
3.4 Glybera: Pricing Will Determine the Future of this Promising Gene Therapy
3.4.1 Glybera Pricing Strategy
3.4.2 Glybera Revenue Forecast, 2014-2026
3.5 Neovasculgen: Russia’s First Gene Therapy
3.5.1 Neovasculgen: Historical Performance and Revenue Forecast 2014-2026

4. Gene Therapy World Market and Disease Submarkets, 2014-2026
4.1 The Global Market for Gene Therapy Drug Treatments in 2014
4.2 Gene Therapy Market Forecast, 2014-2026
4.3 Gene Therapy for Cancer
4.3.1 Clinical Trials for Cancer
4.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2014-2026
4.4 Gene Therapy for Rare Diseases
4.4.1 The Rare Disease Treatment Submarket Forecast 2014-2026
4.5 Gene Therapy for Cardiovascular Diseases
4.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2014-2026
4.6 Gene Therapy for Ophthalmologic Diseases
4.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
4.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2014-2026
4.7 Gene Therapy for Other Diseases
4.7.1 The Other Disease Treatment Submarket Forecast 2014-2026
4.8 Changing Market Shares: Cancer Disease Gene Therapies Will Eventually Become Market Leader

5. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future
5.1 UniQure- the First Commercial Stage Gene Therapy Company in the West
5.2 Biogen – Focusing on Ophthalmologic and Rare Disease Gene Therapies
5.3 Bluebird Bio: Gene Editing Technology
5.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
5.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
5.6 Oxford Biomedica: Collaboration as a Strategy
5.7 GenSight Biologics – Novel Mitochondrial Technology Platform
5.8 Gene Therapy and Big Pharma: Collaborations

6. R&D Pipeline Analysis and Forecasts, 2014-2026
6.1 Pipeline
6.2 Pipeline Analysis
6.3 GSK2696273 – GSK
6.4 Collategene (AMG0001) – AnGes MG/Vical
6.5 BC-819 – BioCancell
6.6 BC-821 – BioCancell
6.7 Lenti-D – Bluebird Bio
6.8 LentiGlobin (LentiGlobin BB305) – Bluebird Bio
6.9 SPK-RPE65 – Spark Therapeutics
6.10 SPK-CHM – Spark Therapeutics
6.11 SPK-FIX – Spark Therapeutics/Pfizer
6.12 SPK-TPP1- Spark Therapeutics
6.13 Invossa (TissueGene-C) – TissueGene Inc/Kolon Life Science
6.14 VM202-DPN – ViroMed
6.15 Important Pipeline Technology Developments
6.16 The Future of the Gene Therapy Pipeline

7. Qualitative Analysis of the Gene Therapy Market, 2016-2026
7.1 SWOT Analysis of the Gene Therapy Treatment Market, 2016
7.2 Strengths: A Vast Pipeline for a Wide Range of Indications
7.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
7.4 Opportunities and Threats for the Gene Therapy Drug Market, 2016-2026
7.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
7.6 Threats: Expensive Drugs with Strict Regulations
7.7 National Markets: Regulation of the Gene Therapy Market
7.7.1 Gene Therapy Regulations: Evolving with the Market
7.7.2 US Regulations: Strict Regulation of a Cautious Market
7.7.3 EU Regulations: One Approval So Far
7.7.4 Japanese Regulations: A Rigorous Process

8. Research Interviews from Our Survey
8.1 Interview with Karen Aiach, Founder and CEO of Lysogene, Neuilly-sur-Seine, France
8.1.1 The Origin of Lysogene and its Focus
8.1.2 Strategy and Challenges for Gene Therapy Development
8.1.3 Regulations and Their Effect on the Future of Gene Therapy Development in the EU
8.2 Interview with Dr Fungayi Chidothe, MD, Senior Business Development Manager, Cell Therapy Catapult, London, UK
8.2.1 Cell Therapy Catapult: Supporting the Translation of Research into Marketable Therapies
8.2.2 Trends in the Gene Therapy Industry
8.2.3 The Challenges of Bringing a Gene Therapy to Market
8.2.4 Regulatory and Reimbursement Concerns for Gene Therapies
8.2.5 The Potential and Promise in Gene Therapy Applications
8.3 Interview with Dr Artur Isaev, CEO of HSCI – Human Stem Cells Institute, Moscow, Russia
8.3.1 The Human Stem Cells Institute: Innovation in Russia
8.3.2 Strategies for Marketing Neovasculgen®
8.3.3 The Benefits of the Developed Versus Emerging Marketplace
8.3.4 Challenges of Producing Gene Therapies and a Future Outlook

9. Conclusions from Our Research and Analysis
9.1 The World Gene Therapy Treatment Market: Current World Outlook
9.1.1 Leading Gene Therapy Treatment Submarkets and Products, 2015-2026
9.1.2 Driver for Growth to 2026: A Vast Pipeline of Gene Therapy Products
9.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
9.2 The Future of the Gene Therapy Treatment Market

List of Tables
Table 1.1 Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2013, 2014, and 2015
Table 3.1 Approved Gene Therapies, 2015
Table 3.2 Glybera Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 3.3 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2015
Table 3.4 Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2014-2026
Table 4.1 Leading Gene Therapy Drugs by Revenue ($m), 2015
Table 4.2 World Market Forecasts for Gene Therapy by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2014-2026
Table 4.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2015
Table 4.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2015
Table 4.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2015
Table 4.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2015
Table 4.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2015
Table 4.8 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2015
Table 4.9 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2015
Table 4.10 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2014
Table 4.11 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
Table 4.12 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2015
Table 4.13 Rare Diseases Gene Therapy Pipeline, 2015
Table 4.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
Table 4.15 Cardiovascular Gene Therapy Pipeline, 2015
Table 4.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
Table 4.17 Preclinical Ophthalmologic Pipeline, 2015
Table 4.18 Clinical Ophthalmologic Pipeline, 2015
Table 4.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2015
Table 4.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
Table 4.21 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
Table 4.22 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2014-2020
Table 4.23 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2021-2026
Table 5.1 uniQure Pipeline, 2015
Table 5.2 Spark Therapeutics Collaborations, 2015
Table 5.3 Selected Big Pharma Collaborations in Gene Therapy, 2015
Table 6.1 Promising Gene Therapies in Development, 2015
Table 6.2 Gene Therapies in Phase 3, 2015
Table 6.3 GSK2696273 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 6.4 Collategene Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 6.5 BC-819 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 6.6 Lenti-D Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 6.7 SPK-RPE65 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 6.8 Invossa Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
Table 7.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2016
Table 7.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2015
Table 7.3 Gene Therapy Pipeline for Metabolic Diseases, 2015
Table 7.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2015
Table 7.5 Gene Therapy Pipeline for Viral Diseases, 2015
Table 7.6 Opportunities and Threats of the Gene Therapy Drug Market, 2016
Table 7.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2015
Table 9.1 Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2014, 2016, 2020 and 2026

List of Figures
Figure 1.1 Global Gene Therapy Treatment Market Segmentation Overview, 2016
Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2015
Figure 3.1 Glybera Forecast, Revenue ($m), 2014-2026
Figure 3.2 Neovasculgen Forecast, Revenue ($m), 2014-2026
Figure 4.1 Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2014-2026
Figure 4.2 Cancer Gene Therapy Pipeline by Phase of Development, 2015
Figure 4.3 Global Gene Therapy Market: Market Shares (%) by Indication, 2014
Figure 4.4 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2014-2026
Figure 4.5 Global Gene Therapy Market: Market Shares (%) by Indication, 2015
Figure 4.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2015
Figure 4.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2014-2026
Figure 4.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2015
Figure 4.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2014-2026
Figure 4.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2014-2026
Figure 4.11 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2014-2026
Figure 4.12 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2020
Figure 4.13 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2026
Figure 6.1 Gene Therapies in Clinical Development by Phase, 2015
Figure 6.2 GSK2696273 Forecast, Revenue ($m), 2014-2026
Figure 6.3 Collategene Forecast, Revenue ($m), 2014-2026
Figure 6.4 BC-819 Forecast , Revenue ($m), 2014-2026
Figure 6.5 Lenti-D Forecast, Revenue ($m), 2014-2026
Figure 6.6 SPK-RPE65 Forecast, Revenue ($m), 2014-2026
Figure 6.7 Invossa Forecast, Revenue ($m), 2014-2026
Figure 9.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2014, 2016, 2020, and 2026

【レポートのキーワード】

遺伝子治療、売上、医薬品、がん治療、循環器疾患治療

★調査レポート[遺伝子治療の世界市場:研究開発および売上予測2016-2026] ( Gene Therapy R&D and Revenue Forecasts 2016-2026 : Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs / VGAIN6022516) 販売に関する免責事項
[遺伝子治療の世界市場:研究開発および売上予測2016-2026] ( Gene Therapy R&D and Revenue Forecasts 2016-2026 : Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs / VGAIN6022516) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆